

methyl substituted heterocycles containing oxygen.

Uracil-5-carboxylic acid² (1.00 Gm., 0.0064 mole) and 0.5 ml. of water (0.028 mole) were placed in a steel bomb which was sealed. After cooling the bomb in dry ice-acetone, approximately 45 Gm. of sulfur tetrafluoride³ (0.41 mole) was introduced. This was heated to 100°, agitated for 16 hours and subsequently allowed to cool to room temperature. The volatile material was vented and decomposed in 10% potassium hydroxide solution and the residue was recrystallized several times from water and sublimed giving 0.883 Gm. (77%, m.p. 247–249° dec., reported (1) m.p. 239–241°).

*Anal.*⁴—Calcd. for C₅H₃F₂N₂O₂: C, 33.35; H, 1.68; F, 31.65; N, 15.55. Found: C, 33.49; H, 1.61; F, 31.87; N, 15.69.

The following ultraviolet absorption spectra were recorded: 0.1 N HCl, λ_{\max} . 257 m μ ,

² Nutritional Biochemicals Corp.
³ Organic Chemicals Dept., E. I. duPont de Nemours & Co., Inc.
⁴ Appreciation is expressed to Dr. Earl M. Chamberlin, Merck & Co., Inc., for the analytical data.

Synthesis of Dehydrocycloheximide

Sir:

In addition to our interest in the stereochemistry of cycloheximide (1, 2), we have been concerned with the development of a method for the synthesis of cycloheximide and certain of its degradation products. Recently, Lawes has described the synthesis of anhydrocycloheximide (3); the present communication describes the total synthesis of dehydrocycloheximide.

The method which we selected for the synthesis of dehydrocycloheximide employs the combination of the two fragments, 2,4-dimethylcyclohexanone and glutarimide- β -acetyl chloride. The preparation of (+)-*trans*-2,4-dimethylcyclohexanone (I) was accomplished by thermal deg-

radation of cycloheximide (4). When I was allowed to react with piperidine in benzene solution according to the general procedure of Stork (5), a 47% yield of the enamine (II) was obtained; b.p. 79–82°/2.0 mm., $[\alpha]_D^{26} = +44.5^\circ$ (c = 5.66% in ethanol).

The pharmacological results and the synthesis of this and other analogs will be published in full detail in the future.

- (1) Heidelberger, C., Parsons, D., and Remy, D. C., *J. Am. Chem. Soc.*, **84**, 3597(1962).
- (2) Barone, J. A., Peters, E., and Tickelmann, H., *J. Org. Chem.*, **24**, 198(1959); Inoue, S., Saggiomo, A. J., and Nodiff, E. A., *ibid.*, **26**, 4504(1961); Giner-Sorolla, A., and Bendich, A., *J. Am. Chem. Soc.*, **80**, 5744(1958).
- (3) Whitehead, C. W., *J. Am. Chem. Soc.*, **74**, 4267(1952).
- (4) Hasek, W. R., Smith, W. C., and Engelhardt, V. A., *J. Am. Chem. Soc.*, **82**, 543(1960).
- (5) Martin, D. G., and Pike, J. E., *J. Org. Chem.*, **27**, 4086(1962); Martin, D. G., and Kagan, F., *ibid.*, **27**, 3164(1962).
- (6) Raasch, M. S., *ibid.*, **27**, 1406(1962).

MATHIAS P. MERTES

SOUHEIL E. SAHEB


Department of Pharmaceutical Chemistry
 School of Pharmacy
 University of Kansas
 Lawrence

Received January 25, 1963.

Accepted for publication February 19, 1963.

This work was supported in part by a grant (CV-5639) from the National Cancer Institute, National Institutes of Health, U. S. Public Health Service.

Note added in proof: Preliminary examination of 5-trifluoromethyluracil (NSC-73757) against Sarcoma-180 showed a lack of significant activity. Toxicity was evident at 500 mg./Kg. (2 of six survivors). At 200 mg./Kg. the tumor/control weight ratio was 0.63 (five of six survivors).



chromatography, and the melting and mixture melting points of the synthetic product (IV) with an authentic sample of dehydrocycloheximide (7) revealed that the two products were, in fact, identical.

Our research on the synthesis of IV was initiated on the model enamine (VI) prepared from piperidine and 2-methylcyclohexanone (V) since it has been suggested that enamines which are substituted in the 2-position might not undergo reaction (5). However, we have found that enamines of this type are reactive; thus, condensation of the model enamine (VI) with glutarimide- β -acetyl chloride (III) resulted in the formation of a 25% yield of (\pm)-nordehydrocycloheximide (VII), thereby establishing that acylation at the 6-position is feasible. The reason that the yield of VII and of IV was not over 50% is most probably caused by the fact that the distilled enamine is actually a mixture of double bond isomers in which the double bond is either at C₁-C₆ or C₁-C₂. Since only that isomer in which the double bond is at C₁-C₆ (II or VI) can give IV or VII, the reduction in yield can readily be understood. Evidence that the enamine is a mixture of double bond isomers is available from its infrared spectrum. Thus, in the C=C region, II exhibits two peaks, one at 1680 cm.⁻¹ and one at 1645 cm.⁻¹ The enamine VI also exhibits peaks at 1670 cm.⁻¹ and 1640 cm.⁻¹ However, the enamine prepared from cyclohexanone and piperidine exhibits only one peak in the C=C region at 1645 cm.⁻¹ This result would be predicted for this enamine since it cannot exist in an isomeric form as can II or VI.

One final point which requires comment is the stereochemical assignment of the methyl groups

of dehydrocycloheximide (IV). It has been established that in cycloheximide the methyl groups are *trans* (1, 4), but no proof of the stereochemistry of dehydrocycloheximide has been reported. However, the present synthesis of dehydrocycloheximide (IV) establishes that the methyl groups are *trans* since IV was synthesized from (+)-*trans*-2,4-dimethylcyclohexanone (I). It might be argued that the α -methyl group of I could be isomerized during the preparation of the enamine, but this hypothesis was shown to be rather unimportant when it was found that the acid catalyzed hydrolysis of the enamine (II) regenerated a 75% yield of (+)-*trans*-2,4-dimethylcyclohexanone (I). This result therefore offers strong support to the assignment of the *trans* methyl groups in dehydrocycloheximide (IV).

- (1) Schaeffer, H. J., and Jain, V. K., *THIS JOURNAL*, **50**, 1048(1961).
- (2) Schaeffer, H. J., and Jain, V. K., *ibid.*, in press.
- (3) Lawes, B. C., *J. Am. Chem. Soc.*, **82**, 6413(1960).
- (4) Lawes, B. C., *ibid.*, **84**, 239(1962).
- (5) Stork, G., Terrell, R., and Szmuszkovicz, J., *ibid.*, **76**, 2029(1954).
- (6) Phillips, D. D., Acitelli, M. A., and Meinwald, J., *ibid.*, **79**, 3517(1957).
- (7) Kornfeld, E. C., Jones, R. J., and Parke, T. V., *ibid.*, **71**, 150(1949).
- (8) Lemin, A. J., and Ford, J. H., *J. Org. Chem.*, **25**, 344(1960).

HOWARD J. SCHAEFFER
VIJAY K. JAIN

Department of Medicinal Chemistry
School of Pharmacy
State University of New York at Buffalo
Buffalo

Received January 25, 1963.

Accepted for publication February 13, 1963.

The research described in this paper was submitted by V. K. Jain in partial fulfillment of the Ph.D. degree requirements.

This investigation was supported in part by a Public Health Service research career program award CA-K6-18718 from the National Cancer Institute and in part by Research Grant CY-4812 from the National Cancer Institute, National Institutes of Health, Public Health Service.

Book Notices

Year Book of Drug Therapy. 1962-1963 Series.

Edited by HARRY BECKMAN. Year Book Medical Publishers, Inc., 35 E. Wacker Drive, Chicago 1, Ill., 1962. 648 pp. 13 × 20 cm. Price \$8.50.

A new section has been added to this revised volume entitled "Precautions," replacing the section entitled "Critical Evaluation of the Year's New Drugs." As with prior editions, the major presentation is through abstracts covering reports of new therapeutic or prophylactic uses and applications of drugs during the "series year." The abstracts are well written in the concise and meaty form which has become characteristic of this series. In the newly added section, sketches of accumulated experience regarding the toxic actualities and poten-

tialities of drugs in current use will be of invaluable assistance to pharmaceutical and medical personnel.

Protein Metabolism. Edited by F. GROSS. Springer Verlag, Berlin-Wilmersdorf, Heidelberg Platz 3/, West Berlin, Germany, 1962. xi + 521 pp. 14 × 20.5 cm.

The proceedings of an international symposium are reported—the fourth in a series of such symposia sponsored by Ciba, Ltd., Basle. Major topics covered by the participants include: Action of hormones at the cellular level; Factors influencing protein metabolism in the organism; Evaluation and mode of action of anabolic steroids; Protein metabolism in human pathological states; and